A 12 week, randomized, double blind parallel group prospective dose ranging study of ZYH1 with an open pioglitazone arm to evaluate the efficacy on dyslipidemia in patients with Impaired Glucose tolerance Test.

Trial Profile

A 12 week, randomized, double blind parallel group prospective dose ranging study of ZYH1 with an open pioglitazone arm to evaluate the efficacy on dyslipidemia in patients with Impaired Glucose tolerance Test.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 30 Aug 2016

At a glance

  • Drugs Saroglitazar (Primary) ; Pioglitazone
  • Indications Dyslipidaemias; Glucose intolerance
  • Focus Therapeutic Use
  • Sponsors Cadila Healthcare
  • Most Recent Events

    • 21 Mar 2013 Status changed from completed to discontinued as reported by Clinical Trials Registry - India record.
    • 08 Sep 2010 Status changed from discontinued to completed as reported by Clinical Trials Registry - India record.
    • 12 Mar 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top